Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess.
Spruce Biosciences trades on the Nasdaq Global Market under the symbol “SPRB”.
Spruce Biosciences’ headquarters are located at 611 Gateway Boulevard, Suite 740, South San Francisco, CA 94080.
The biographies of Spruce Biosciences’ directors are available in the “Board of Directors” section of our company website here.
The biographies of Spruce Biosciences’ management are available in the “Management Team” section of our company website here.
Spruce Biosciences’ fiscal year ends December 31st.
Spruce Biosciences’ independent auditor is BDO USA, LLP.
Address:
300 Park Avenue Suite 900
San Jose, CA 95110
Phone: 408-278-0220
Spruce Biosciences’ outside legal counsel is Cooley LLP.
Address:
101 California Street
5th Floor
San Francisco, CA 94111-5800
Phone: (415) 693-2000
Spruce Biosciences’ CUSIP number is 85209E 109.
Computershare
USA +1 (800) 736-3001
(US, Canada, Puerto Rico)
+1 (781) 575 3100 (non-US)
web.queries@computershare.com
Shareholder Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY 40233
Shareholder Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202
Please see the "Events & Presentations" section of our company website here for a listing of upcoming earnings announcements and other key events.
You can contact Spruce Biosciences’ Investor Relations via email by clicking here.
You can contact Spruce Biosciences’ Media Relations via email by clicking here.
Spruce Biosciences was incorporated in Delaware in April 2016.
If your shares are held in street name (by your broker), you must notify the securities firm holding your stock. If you hold stock certificates in your own name, address changes should be submitted in writing via U.S. mail to our transfer agent, Computershare:
For written requests by regular mail:
Computershare
P.O. Box 505000
Louisville, KY 40233
For written requests by overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202